VERA

Vera Therapeutics, Inc.

NasdaqAdd to watchlist

Healthcare · Biotechnology

$34.00

−$0.27−0.79%

Delayed · 2026-09-18T20:00:00.000Z · marketstack

9 of 18 open-market sales on file ran under a pre-arranged trading plan ($7.04M), 9 did not. Who, and when

Aug 24, 2026$34.00

+$0.28+0.83%over 1M

Session

Day range62% of range

$33.08$34.56

Fundamentals

Visualize fundamentals and more

Market cap: 2.44B
P/E ratio: -

Risk factors, year on year

Item 1AFeb 2026 10-KFeb 2025

added: 85
dropped: 90
re-drafted: 89

Out of 304 passages in this year’s Item 1A.

New this year

We have incurred net losses since inception and have never generated revenue from product sales. We expect to continue to incur net losses at least until we have one or more approved products that achieve commercial success.

174 more passages are on Bespoke

Bespoke Create a free account

Free, no card, and it does not expire. See what the paid plans add

What it says it is exposed to

From Item 1A of its most recent 10-K, filed February 2026.

FDA approval
Reimbursement
Data privacy
Export controls
Tariffs
Russia and Ukraine
Inflation
Litigation

And 10 more.

FDA approval
Our operations have consumed substantial amounts of cash since inception, and we expect our expenses will increase in connection with our ongoing activities, particularly as we continue to conduct clinical trials of, and seek marketing approval for, our …

7 more themes are on Measure

Measure Create a free account

Free, no card, and it does not expire. See what the paid plans add

Recent activity

21 more events are on Measure

Measure Create a free account

Free, no card, and it does not expire. See what the paid plans add

Discussion

No comments yet

Set a username to join the discussion. It’s the only thing shown next to what you post, never your email address.

Comments are written by other users. Nothing here is investment advice and nothing is checked for accuracy.

Updated Sep 18, 2026 · the last close

Vera Therapeutics, Inc. investor relations

What VERA has filed with the SEC. This is not Vera Therapeutics, Inc.’s own investor relations site: these filings are the primary source that site publishes from.

Companies like Vera Therapeutics, Inc.

Also filed under Biotechnology, ranked by how closely they sit beside VERA.

MRNAModerna, Inc.compare with VERA
ROIVRoivant Sciences Ltd.compare with VERA
VRTXVertex Pharmaceuticals Inc. / MA

XENEXenon Pharmaceuticals Inc.compare with VERA

NVONovo Nordisk A Scompare with VERA

Ask about Vera Therapeutics, Inc.

The assistant answers from what VERA has actually filed: 6 annual reports filed with the SEC, 43 Form 4 filings from the last year and 3 funds that hold it. Every figure in a reply links to the filing it came from, so an answer can be checked rather than believed.

Press one and the answer appears right here on the page, from VERA's filings and figures. One a day without an account; a free account has its own, and no card.

See how much of Vera Therapeutics, Inc. each of these investors holds, and every quarter they moved.

Ten seconds. No card. Nothing to cancel.

No card, no broker connection.

Continue with Google

What an account lets you do with Vera Therapeutics, Inc.

Be told the moment a VERA insider trades
Put Vera Therapeutics, Inc. on a watchlist for a free alert, the bell and a daily email, when a Form 4 worth a row is filed, with vesting and automatic tax sales already struck out so what lands is a decision, not paperwork.
The full filing historyMeasure
Ask what growth the price is already betting on
Vera Therapeutics, Inc.'s income statement, balance sheet and cash flow as filed, and the ratios computed from them, plus a reverse DCF that holds today's price fixed and solves for the growth it requires.
The reverse DCFMeasure
Watch the same stakes the professionals are watching
Every tracked position priced at the quarter it was filed and diffed against the one before it: how big a bet each one is, and by how much it changed.
Every position, sizedMeasure
Interrogate the filing, not the internet
Ask anything about Vera Therapeutics, Inc.'s fundamentals. The assistant answers from its own filings and cites the figure, never a guess from the open web.

Create a free account See what the paid plans add

Free, no card, and it does not expire.

What it says it is exposed to

From Item 1A of its most recent 10-K, filed February 2026.

FDA approval
Reimbursement
Data privacy
Export controls
Tariffs
Russia and Ukraine
Inflation
Litigation

And 10 more.

FDA approval
Our operations have consumed substantial amounts of cash since inception, and we expect our expenses will increase in connection with our ongoing activities, particularly as we continue to conduct clinical trials of, and seek marketing approval for, our …

7 more themes are on Measure

Measure Create a free account

Free, no card, and it does not expire. See what the paid plans add

Risk factors, year on year

Item 1AFeb 2026 10-KFeb 2025

added: 85
dropped: 90
re-drafted: 89

Out of 304 passages in this year’s Item 1A.

New this year

We have incurred net losses since inception and have never generated revenue from product sales. We expect to continue to incur net losses at least until we have one or more approved products that achieve commercial success.

174 more passages are on Bespoke

Bespoke Create a free account

Free, no card, and it does not expire. See what the paid plans add